ID   MYH10_HUMAN             Reviewed;        1976 AA.
AC   P35580; B2RWP9; D3DTS1; F8VTL3; Q12989; Q149N3; Q149N4; Q16087; Q4LE45;
AC   Q6PK16; Q9BWG0;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 3.
DT   28-JUN-2023, entry version 223.
DE   RecName: Full=Myosin-10;
DE   AltName: Full=Cellular myosin heavy chain, type B;
DE   AltName: Full=Myosin heavy chain 10;
DE   AltName: Full=Myosin heavy chain, non-muscle IIb;
DE   AltName: Full=Non-muscle myosin heavy chain B;
DE            Short=NMMHC-B;
DE   AltName: Full=Non-muscle myosin heavy chain IIb;
DE            Short=NMMHC II-b;
DE            Short=NMMHC-IIB;
GN   Name=MYH10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7499478; DOI=10.1007/bf00114503;
RA   Phillips C.L., Yamakawa K., Adelstein R.S.;
RT   "Cloning of the cDNA encoding human nonmuscle myosin heavy chain-B and
RT   analysis of human tissues with isoform-specific antibodies.";
RL   J. Muscle Res. Cell Motil. 16:379-389(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8690889;
RA   Abdelhaleem M.M., Hameed S., Klassen D., Greenberg A.H.;
RT   "Leukophysin: an RNA helicase A-related molecule identified in cytotoxic T
RT   cell granules and vesicles.";
RL   J. Immunol. 156:2026-2035(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R.,
RA   Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long cDNAs
RT   encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 5).
RC   TISSUE=Eye, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 63-722 (ISOFORM 1).
RX   PubMed=1860190; DOI=10.1161/01.res.69.2.530;
RA   Simons M., Wang M., McBride O.W., Kawamoto S., Yamakawa K., Gdula D.,
RA   Adelstein R.S., Weir L.;
RT   "Human nonmuscle myosin heavy chains are encoded by two genes located on
RT   different chromosomes.";
RL   Circ. Res. 69:530-539(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 211-301 (ISOFORM 2), ALTERNATIVE SPLICING
RP   (ISOFORM 3), AND TISSUE SPECIFICITY.
RX   PubMed=7782316; DOI=10.1074/jbc.270.24.14533;
RA   Itoh K., Adelstein R.S.;
RT   "Neuronal cell expression of inserted isoforms of vertebrate nonmuscle
RT   myosin heavy chain II-B.";
RL   J. Biol. Chem. 270:14533-14540(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1751-1976.
RX   PubMed=7916668; DOI=10.1161/01.res.73.6.1000;
RA   Aikawa M., Sivam P.N., Kuro-O M., Kimura K., Nakahara K., Takewaki S.,
RA   Ueda M., Yamaguchi H., Yazaki Y., Periasamy M.;
RT   "Human smooth muscle myosin heavy chain isoforms as molecular markers for
RT   vascular development and atherosclerosis.";
RL   Circ. Res. 73:1000-1012(1993).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   INTERACTION WITH PLEKHG6.
RX   PubMed=16721066; DOI=10.4161/cc.5.11.2815;
RA   Wu D., Asiedu M., Adelstein R.S., Wei Q.;
RT   "A novel guanine nucleotide exchange factor MyoGEF is required for
RT   cytokinesis.";
RL   Cell Cycle 5:1234-1239(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1939; SER-1952 AND SER-1956,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1956, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1939 AND SER-1956, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-442 AND LYS-1645, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [19]
RP   INTERACTION WITH ECPAS.
RX   PubMed=20682791; DOI=10.1074/jbc.m110.154120;
RA   Gorbea C., Pratt G., Ustrell V., Bell R., Sahasrabudhe S., Hughes R.E.,
RA   Rechsteiner M.;
RT   "A protein interaction network for Ecm29 links the 26 S proteasome to
RT   molecular motors and endosomal components.";
RL   J. Biol. Chem. 285:31616-31633(2010).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH LARP6.
RX   PubMed=20603131; DOI=10.1016/j.jmb.2010.06.057;
RA   Cai L., Fritz D., Stefanovic L., Stefanovic B.;
RT   "Nonmuscle myosin-dependent synthesis of type I collagen.";
RL   J. Mol. Biol. 401:564-578(2010).
RN   [21]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20052411; DOI=10.1371/journal.pone.0008560;
RA   Betapudi V.;
RT   "Myosin II motor proteins with different functions determine the fate of
RT   lamellipodia extension during cell spreading.";
RL   PLoS ONE 5:E8560-E8560(2010).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1956, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-214 (ISOFORMS 2 AND 4), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1145 AND SER-1938,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214 (ISOFORMS 2 AND 4), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   INTERACTION WITH MCC, AND SUBCELLULAR LOCATION.
RX   PubMed=22480440; DOI=10.1016/j.bbamcr.2012.03.011;
RA   Pangon L., Van Kralingen C., Abas M., Daly R.J., Musgrove E.A.,
RA   Kohonen-Corish M.R.;
RT   "The PDZ-binding motif of MCC is phosphorylated at position -1 and controls
RT   lamellipodia formation in colon epithelial cells.";
RL   Biochim. Biophys. Acta 1823:1058-1067(2012).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1935; SER-1937; SER-1952 AND
RP   SER-1956, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1935; SER-1939; SER-1952;
RP   SER-1956 AND THR-1960, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214
RP   (ISOFORMS 2 AND 4), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   INTERACTION WITH CFAP95.
RX   PubMed=28345668; DOI=10.1038/srep45311;
RA   Zhou S., Liu Y., Ma Y., Zhang X., Li Y., Wen J.;
RT   "C9ORF135 encodes a membrane protein whose expression is related to
RT   pluripotency in human embryonic stem cells.";
RL   Sci. Rep. 7:45311-45311(2017).
RN   [29]
RP   VARIANT 908-GLU--GLU-1976 DEL.
RX   PubMed=25003005; DOI=10.4161/rdis.26144;
RA   Tuzovic L., Yu L., Zeng W., Li X., Lu H., Lu H.M., Gonzalez K.D.,
RA   Chung W.K.;
RT   "A human de novo mutation in MYH10 phenocopies the loss of function
RT   mutation in mice.";
RL   Rare Dis. 1:E26144-E26144(2013).
RN   [30]
RP   VARIANT CYS-270.
RX   PubMed=25356899; DOI=10.1371/journal.pgen.1004772;
RA   Hamdan F.F., Srour M., Capo-Chichi J.M., Daoud H., Nassif C., Patry L.,
RA   Massicotte C., Ambalavanan A., Spiegelman D., Diallo O., Henrion E.,
RA   Dionne-Laporte A., Fougerat A., Pshezhetsky A.V., Venkateswaran S.,
RA   Rouleau G.A., Michaud J.L.;
RT   "De novo mutations in moderate or severe intellectual disability.";
RL   PLoS Genet. 10:E1004772-E1004772(2014).
CC   -!- FUNCTION: Cellular myosin that appears to play a role in cytokinesis,
CC       cell shape, and specialized functions such as secretion and capping.
CC       Involved with LARP6 in the stabilization of type I collagen mRNAs for
CC       CO1A1 and CO1A2. During cell spreading, plays an important role in
CC       cytoskeleton reorganization, focal contacts formation (in the central
CC       part but not the margins of spreading cells), and lamellipodial
CC       extension; this function is mechanically antagonized by MYH9.
CC       {ECO:0000269|PubMed:20052411, ECO:0000269|PubMed:20603131}.
CC   -!- SUBUNIT: Myosin is a hexameric protein that consists of 2 heavy chain
CC       subunits (MHC), 2 alkali light chain subunits (MLC) and 2 regulatory
CC       light chain subunits (MLC-2). Interacts with PLEKHG6 (PubMed:16721066).
CC       Interacts with ECPAS (PubMed:20682791). Interacts with KIF26B (By
CC       similarity). Interacts with LARP6 (PubMed:20603131). Interacts with MCC
CC       (PubMed:22480440). Interacts with CFAP95 (PubMed:28345668).
CC       {ECO:0000250|UniProtKB:Q61879, ECO:0000269|PubMed:16721066,
CC       ECO:0000269|PubMed:20603131, ECO:0000269|PubMed:20682791,
CC       ECO:0000269|PubMed:22480440, ECO:0000269|PubMed:28345668}.
CC   -!- SUBCELLULAR LOCATION: Cell projection, lamellipodium
CC       {ECO:0000269|PubMed:20052411, ECO:0000269|PubMed:22480440}.
CC       Note=Colocalizes with MCC at the leading edge of migrating cells.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P35580-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35580-2; Sequence=VSP_022013;
CC       Name=3;
CC         IsoId=P35580-3; Sequence=VSP_022014;
CC       Name=4;
CC         IsoId=P35580-4; Sequence=VSP_046033, VSP_022014;
CC       Name=5;
CC         IsoId=P35580-5; Sequence=VSP_054974;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in cerebellum and spinal
CC       chord. Isoform 2 is expressed in cerebrum and retina. Isoform 3 is
CC       expressed in the cerebrum and to a much lower extent in cerebellum.
CC       {ECO:0000269|PubMed:7782316}.
CC   -!- DOMAIN: The rodlike tail sequence is highly repetitive, showing cycles
CC       of a 28-residue repeat pattern composed of 4 heptapeptides,
CC       characteristic for alpha-helical coiled coils.
CC   -!- PTM: Phosphorylated by ABL2. {ECO:0000250}.
CC   -!- DISEASE: Note=Associated with severe intellectual disability,
CC       microcephaly, and feeding difficulties as well as cerebral atrophy.
CC       {ECO:0000269|PubMed:25003005, ECO:0000269|PubMed:25356899}.
CC   -!- SIMILARITY: Belongs to the TRAFAC class myosin-kinesin ATPase
CC       superfamily. Myosin family. {ECO:0000305}.
CC   -!- CAUTION: Represents a conventional non-muscle myosin. This protein
CC       should not be confused with the unconventional myosin-10 (MYO10).
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE06108.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M69181; AAA99177.1; -; mRNA.
DR   EMBL; AB210026; BAE06108.1; ALT_INIT; mRNA.
DR   EMBL; AC011061; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025518; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC026130; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90046.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90047.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90048.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90049.1; -; Genomic_DNA.
DR   EMBL; BC000280; AAH00280.1; -; mRNA.
DR   EMBL; BC008968; AAH08968.1; -; mRNA.
DR   EMBL; BC117690; AAI17691.1; -; mRNA.
DR   EMBL; BC117691; AAI17692.1; -; mRNA.
DR   EMBL; BC144668; AAI44669.1; -; mRNA.
DR   EMBL; BC150634; AAI50635.1; -; mRNA.
DR   EMBL; U15618; AAA87712.1; -; mRNA.
DR   EMBL; S67247; AAB28952.1; -; mRNA.
DR   CCDS; CCDS11144.1; -. [P35580-1]
DR   CCDS; CCDS58515.1; -. [P35580-4]
DR   CCDS; CCDS73984.1; -. [P35580-5]
DR   PIR; A59252; A59252.
DR   PIR; I65769; I65769.
DR   RefSeq; NP_001242941.1; NM_001256012.1. [P35580-4]
DR   RefSeq; NP_001243024.1; NM_001256095.1. [P35580-5]
DR   RefSeq; NP_005955.3; NM_005964.3. [P35580-1]
DR   RefSeq; XP_016880169.1; XM_017024680.1.
DR   RefSeq; XP_016880170.1; XM_017024681.1. [P35580-1]
DR   RefSeq; XP_016880171.1; XM_017024682.1.
DR   PDB; 4PD3; X-ray; 2.84 A; A/B=1-782.
DR   PDBsum; 4PD3; -.
DR   AlphaFoldDB; P35580; -.
DR   SMR; P35580; -.
DR   BioGRID; 110713; 328.
DR   CORUM; P35580; -.
DR   DIP; DIP-31110N; -.
DR   IntAct; P35580; 75.
DR   MINT; P35580; -.
DR   STRING; 9606.ENSP00000353590; -.
DR   BindingDB; P35580; -.
DR   ChEMBL; CHEMBL4105746; -.
DR   CarbonylDB; P35580; -.
DR   GlyCosmos; P35580; 1 site, 2 glycans.
DR   GlyGen; P35580; 2 sites, 2 O-linked glycans (2 sites).
DR   iPTMnet; P35580; -.
DR   MetOSite; P35580; -.
DR   PhosphoSitePlus; P35580; -.
DR   SwissPalm; P35580; -.
DR   BioMuta; MYH10; -.
DR   DMDM; 215274129; -.
DR   EPD; P35580; -.
DR   jPOST; P35580; -.
DR   MassIVE; P35580; -.
DR   MaxQB; P35580; -.
DR   PaxDb; P35580; -.
DR   PeptideAtlas; P35580; -.
DR   PRIDE; P35580; -.
DR   ProteomicsDB; 28641; -.
DR   ProteomicsDB; 55095; -. [P35580-1]
DR   ProteomicsDB; 55096; -. [P35580-2]
DR   ProteomicsDB; 55097; -. [P35580-3]
DR   Antibodypedia; 24686; 192 antibodies from 31 providers.
DR   DNASU; 4628; -.
DR   Ensembl; ENST00000269243.8; ENSP00000269243.4; ENSG00000133026.14. [P35580-1]
DR   Ensembl; ENST00000360416.8; ENSP00000353590.4; ENSG00000133026.14. [P35580-4]
DR   Ensembl; ENST00000379980.8; ENSP00000369315.5; ENSG00000133026.14. [P35580-5]
DR   Ensembl; ENST00000686654.1; ENSP00000508862.1; ENSG00000133026.14. [P35580-4]
DR   Ensembl; ENST00000687178.1; ENSP00000509748.1; ENSG00000133026.14. [P35580-5]
DR   Ensembl; ENST00000688902.1; ENSP00000509091.1; ENSG00000133026.14. [P35580-4]
DR   Ensembl; ENST00000693441.1; ENSP00000509241.1; ENSG00000133026.14. [P35580-4]
DR   GeneID; 4628; -.
DR   KEGG; hsa:4628; -.
DR   MANE-Select; ENST00000360416.8; ENSP00000353590.4; NM_001256012.3; NP_001242941.1. [P35580-4]
DR   UCSC; uc002gll.5; human. [P35580-1]
DR   AGR; HGNC:7568; -.
DR   CTD; 4628; -.
DR   DisGeNET; 4628; -.
DR   GeneCards; MYH10; -.
DR   HGNC; HGNC:7568; MYH10.
DR   HPA; ENSG00000133026; Low tissue specificity.
DR   MalaCards; MYH10; -.
DR   MIM; 160776; gene.
DR   neXtProt; NX_P35580; -.
DR   OpenTargets; ENSG00000133026; -.
DR   PharmGKB; PA31366; -.
DR   VEuPathDB; HostDB:ENSG00000133026; -.
DR   eggNOG; KOG0160; Eukaryota.
DR   eggNOG; KOG0161; Eukaryota.
DR   GeneTree; ENSGT00940000155159; -.
DR   HOGENOM; CLU_000192_8_0_1; -.
DR   InParanoid; P35580; -.
DR   OMA; MQAHIQX; -.
DR   OrthoDB; 2877572at2759; -.
DR   PhylomeDB; P35580; -.
DR   TreeFam; TF333601; -.
DR   PathwayCommons; P35580; -.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5625900; RHO GTPases activate CIT.
DR   Reactome; R-HSA-5627117; RHO GTPases Activate ROCKs.
DR   Reactome; R-HSA-5627123; RHO GTPases activate PAKs.
DR   SignaLink; P35580; -.
DR   SIGNOR; P35580; -.
DR   BioGRID-ORCS; 4628; 20 hits in 1164 CRISPR screens.
DR   ChiTaRS; MYH10; human.
DR   GeneWiki; MYH10; -.
DR   GenomeRNAi; 4628; -.
DR   Pharos; P35580; Tchem.
DR   PRO; PR:P35580; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P35580; protein.
DR   Bgee; ENSG00000133026; Expressed in blood vessel layer and 211 other tissues.
DR   ExpressionAtlas; P35580; baseline and differential.
DR   Genevisible; P35580; HS.
DR   GO; GO:0042641; C:actomyosin; IDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IMP:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0016459; C:myosin complex; NAS:UniProtKB.
DR   GO; GO:0032982; C:myosin filament; IBA:GO_Central.
DR   GO; GO:0016460; C:myosin II complex; IDA:UniProtKB.
DR   GO; GO:0097513; C:myosin II filament; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0005844; C:polysome; IMP:UniProtKB.
DR   GO; GO:0001725; C:stress fiber; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; NAS:UniProtKB.
DR   GO; GO:0051015; F:actin filament binding; IDA:MGI.
DR   GO; GO:0043531; F:ADP binding; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IDA:MGI.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0000146; F:microfilament motor activity; IDA:MGI.
DR   GO; GO:0048027; F:mRNA 5'-UTR binding; IDA:UniProtKB.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:UniProtKB.
DR   GO; GO:0030048; P:actin filament-based movement; IDA:MGI.
DR   GO; GO:0031032; P:actomyosin structure organization; IMP:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0000281; P:mitotic cytokinesis; IDA:MGI.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IBA:GO_Central.
DR   CDD; cd14920; MYSc_Myh10; 1.
DR   Gene3D; 1.10.10.820; -; 1.
DR   Gene3D; 1.10.287.1490; -; 1.
DR   Gene3D; 1.20.5.340; -; 4.
DR   Gene3D; 1.20.5.4820; -; 1.
DR   Gene3D; 1.20.58.530; -; 1.
DR   Gene3D; 6.10.250.2420; -; 1.
DR   Gene3D; 3.40.850.10; Kinesin motor domain; 1.
DR   Gene3D; 2.30.30.360; Myosin S1 fragment, N-terminal; 1.
DR   Gene3D; 1.20.120.720; Myosin VI head, motor domain, U50 subdomain; 1.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   InterPro; IPR036961; Kinesin_motor_dom_sf.
DR   InterPro; IPR001609; Myosin_head_motor_dom.
DR   InterPro; IPR004009; Myosin_N.
DR   InterPro; IPR008989; Myosin_S1_N.
DR   InterPro; IPR002928; Myosin_tail.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR45615; MYOSIN HEAVY CHAIN, NON-MUSCLE; 1.
DR   PANTHER; PTHR45615:SF24; MYOSIN-10; 1.
DR   Pfam; PF00612; IQ; 1.
DR   Pfam; PF00063; Myosin_head; 1.
DR   Pfam; PF02736; Myosin_N; 1.
DR   Pfam; PF01576; Myosin_tail_1; 1.
DR   PRINTS; PR00193; MYOSINHEAVY.
DR   SMART; SM00015; IQ; 1.
DR   SMART; SM00242; MYSc; 1.
DR   SUPFAM; SSF90257; Myosin rod fragments; 6.
DR   SUPFAM; SSF50084; Myosin S1 fragment, N-terminal domain; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS50096; IQ; 1.
DR   PROSITE; PS51456; MYOSIN_MOTOR; 1.
DR   PROSITE; PS51844; SH3_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin-binding; Alternative splicing;
KW   ATP-binding; Calmodulin-binding; Cell adhesion; Cell projection;
KW   Cell shape; Coiled coil; Disease variant; Methylation; Motor protein;
KW   Myosin; Nucleotide-binding; Phosphoprotein; Reference proteome.
FT   CHAIN           1..1976
FT                   /note="Myosin-10"
FT                   /id="PRO_0000123421"
FT   DOMAIN          31..81
FT                   /note="Myosin N-terminal SH3-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01190"
FT   DOMAIN          85..783
FT                   /note="Myosin motor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00782"
FT   DOMAIN          786..815
FT                   /note="IQ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00116"
FT   REGION          661..683
FT                   /note="Actin-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00782"
FT   REGION          1127..1147
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1697..1728
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1872..1976
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          845..1976
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        1697..1717
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1872..1915
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1950..1965
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         178..185
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         18
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61879"
FT   MOD_RES         442
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         1145
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1241
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61879"
FT   MOD_RES         1301
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61879"
FT   MOD_RES         1645
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         1930
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61879"
FT   MOD_RES         1935
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1937
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1938
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1939
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1940
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61879"
FT   MOD_RES         1952
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1956
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18318008,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1960
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1975
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JLT0"
FT   VAR_SEQ         211
FT                   /note="P -> PQESPKPVKHQSGSLLY (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7782316"
FT                   /id="VSP_022013"
FT   VAR_SEQ         211
FT                   /note="P -> PQESPKPVKHQ (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_046033"
FT   VAR_SEQ         211
FT                   /note="P -> PESPKPVKHQ (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_054974"
FT   VAR_SEQ         621
FT                   /note="D -> DEIQNIQRASFYDSVSGLHEPP (in isoform 3 and
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_022014"
FT   VARIANT         270
FT                   /note="R -> C (probable disease-associated variant found in
FT                   a patient with severe intellectual disease, microcephaly
FT                   and feeding difficulties as well as cerebral atrophy;
FT                   dbSNP:rs727504231)"
FT                   /evidence="ECO:0000269|PubMed:25356899"
FT                   /id="VAR_078649"
FT   VARIANT         908..1976
FT                   /note="Missing (probable disease-associated variant found
FT                   in a patient with intrauterine growth restriction,
FT                   microcephaly, developmental delay, failure to thrive,
FT                   congenital bilateral hip dysplasia, cerebral and cerebellar
FT                   atrophy, hydrocephalus and congenital diaphragmatic
FT                   hernia)"
FT                   /evidence="ECO:0000269|PubMed:25003005"
FT                   /id="VAR_078650"
FT   CONFLICT        800
FT                   /note="Y -> C (in Ref. 1; AAA99177)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        943..944
FT                   /note="NE -> KK (in Ref. 5; AAH08968)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1429
FT                   /note="L -> P (in Ref. 5; AAI17691)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1751
FT                   /note="N -> D (in Ref. 9; AAB28952)"
FT                   /evidence="ECO:0000305"
FT   TURN            9..14
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          36..39
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          41..49
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          57..65
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          68..75
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           82..84
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           90..92
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           98..109
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   TURN            110..112
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          115..118
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          121..125
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           136..141
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           154..167
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          172..178
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           180..182
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           184..198
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           216..218
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           221..229
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          237..240
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          242..250
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          256..264
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           269..272
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           282..290
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           293..298
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           304..306
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           322..335
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           340..357
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           379..384
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           389..397
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           414..442
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          453..461
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           471..501
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           511..514
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           516..522
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           531..538
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           546..556
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          567..569
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          572..578
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          583..586
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           591..594
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           601..608
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           613..618
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           653..668
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          671..679
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           692..702
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           704..711
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          717..720
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           721..728
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           729..731
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   TURN            733..735
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           745..754
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          760..763
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   STRAND          765..770
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   HELIX           774..782
FT                   /evidence="ECO:0007829|PDB:4PD3"
FT   MOD_RES         P35580-2:214
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         P35580-4:214
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
SQ   SEQUENCE   1976 AA;  228999 MW;  A7C91944EBC2368F CRC64;
     MAQRTGLEDP ERYLFVDRAV IYNPATQADW TAKKLVWIPS ERHGFEAASI KEERGDEVMV
     ELAENGKKAM VNKDDIQKMN PPKFSKVEDM AELTCLNEAS VLHNLKDRYY SGLIYTYSGL
     FCVVINPYKN LPIYSENIIE MYRGKKRHEM PPHIYAISES AYRCMLQDRE DQSILCTGES
     GAGKTENTKK VIQYLAHVAS SHKGRKDHNI PGELERQLLQ ANPILESFGN AKTVKNDNSS
     RFGKFIRINF DVTGYIVGAN IETYLLEKSR AVRQAKDERT FHIFYQLLSG AGEHLKSDLL
     LEGFNNYRFL SNGYIPIPGQ QDKDNFQETM EAMHIMGFSH EEILSMLKVV SSVLQFGNIS
     FKKERNTDQA SMPENTVAQK LCHLLGMNVM EFTRAILTPR IKVGRDYVQK AQTKEQADFA
     VEALAKATYE RLFRWLVHRI NKALDRTKRQ GASFIGILDI AGFEIFELNS FEQLCINYTN
     EKLQQLFNHT MFILEQEEYQ REGIEWNFID FGLDLQPCID LIERPANPPG VLALLDEECW
     FPKATDKTFV EKLVQEQGSH SKFQKPRQLK DKADFCIIHY AGKVDYKADE WLMKNMDPLN
     DNVATLLHQS SDRFVAELWK DVDRIVGLDQ VTGMTETAFG SAYKTKKGMF RTVGQLYKES
     LTKLMATLRN TNPNFVRCII PNHEKRAGKL DPHLVLDQLR CNGVLEGIRI CRQGFPNRIV
     FQEFRQRYEI LTPNAIPKGF MDGKQACERM IRALELDPNL YRIGQSKIFF RAGVLAHLEE
     ERDLKITDII IFFQAVCRGY LARKAFAKKQ QQLSALKVLQ RNCAAYLKLR HWQWWRVFTK
     VKPLLQVTRQ EEELQAKDEE LLKVKEKQTK VEGELEEMER KHQQLLEEKN ILAEQLQAET
     ELFAEAEEMR ARLAAKKQEL EEILHDLESR VEEEEERNQI LQNEKKKMQA HIQDLEEQLD
     EEEGARQKLQ LEKVTAEAKI KKMEEEILLL EDQNSKFIKE KKLMEDRIAE CSSQLAEEEE
     KAKNLAKIRN KQEVMISDLE ERLKKEEKTR QELEKAKRKL DGETTDLQDQ IAELQAQIDE
     LKLQLAKKEE ELQGALARGD DETLHKNNAL KVVRELQAQI AELQEDFESE KASRNKAEKQ
     KRDLSEELEA LKTELEDTLD TTAAQQELRT KREQEVAELK KALEEETKNH EAQIQDMRQR
     HATALEELSE QLEQAKRFKA NLEKNKQGLE TDNKELACEV KVLQQVKAES EHKRKKLDAQ
     VQELHAKVSE GDRLRVELAE KASKLQNELD NVSTLLEEAE KKGIKFAKDA ASLESQLQDT
     QELLQEETRQ KLNLSSRIRQ LEEEKNSLQE QQEEEEEARK NLEKQVLALQ SQLADTKKKV
     DDDLGTIESL EEAKKKLLKD AEALSQRLEE KALAYDKLEK TKNRLQQELD DLTVDLDHQR
     QVASNLEKKQ KKFDQLLAEE KSISARYAEE RDRAEAEARE KETKALSLAR ALEEALEAKE
     EFERQNKQLR ADMEDLMSSK DDVGKNVHEL EKSKRALEQQ VEEMRTQLEE LEDELQATED
     AKLRLEVNMQ AMKAQFERDL QTRDEQNEEK KRLLIKQVRE LEAELEDERK QRALAVASKK
     KMEIDLKDLE AQIEAANKAR DEVIKQLRKL QAQMKDYQRE LEEARASRDE IFAQSKESEK
     KLKSLEAEIL QLQEELASSE RARRHAEQER DELADEITNS ASGKSALLDE KRRLEARIAQ
     LEEELEEEQS NMELLNDRFR KTTLQVDTLN AELAAERSAA QKSDNARQQL ERQNKELKAK
     LQELEGAVKS KFKATISALE AKIGQLEEQL EQEAKERAAA NKLVRRTEKK LKEIFMQVED
     ERRHADQYKE QMEKANARMK QLKRQLEEAE EEATRANASR RKLQRELDDA TEANEGLSRE
     VSTLKNRLRR GGPISFSSSR SGRRQLHLEG ASLELSDDDT ESKTSDVNET QPPQSE
//
